Researchers at UVA developed an AI imaging tool using PET/MR to distinguish treatment effects from tumor progression in glioblastoma patients.
Key Details
- 1AI tool analyzes PET/MR imaging findings in glioblastoma cases.
- 2Distinguishes between tissue changes due to treatment vs. tumor progression.
- 3Current monitoring approaches often require a waiting period of 3+ months.
- 4Faster distinction could enable earlier treatment modification for recurrence.
- 5Method developed by a University of Virginia team.
Why It Matters
Improved differentiation between treatment effects and recurrence could allow clinicians to adjust therapies more quickly, potentially improving outcomes for a highly aggressive brain cancer. This underlines the growing significance of AI-assisted multi-modal imaging in oncology workflows.
Source
Health Imaging
Related News
•AuntMinnie
Deep Learning Chest X-ray Aging Estimates Predict Mortality Risk
Chest x-ray-based biologic aging and aging velocity estimated by deep learning are linked to all-cause and disease-specific mortality.
•Radiology Business
AI Guidance Cuts Novice Ultrasound Exam Time by 34%
AI guidance significantly reduces exam times and enhances diagnostic quality for novice ultrasound operators performing shoulder exams.
•Radiology Business
Lucida Medical Raises $11M for AI-Based Prostate MRI Diagnosis Expansion
Lucida Medical, specializing in AI-assisted prostate cancer diagnosis via MRI, raises $11.4M to drive US FDA approval and platform expansion.